83 related articles for article (PubMed ID: 18391726)
1. Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck.
Cicone F; Loose D; Deron P; Vermeersch H; Signore A; Van de Vyvere F; Scopinaro F; Van de Wiele C
Nucl Med Commun; 2008 May; 29(5):431-5. PubMed ID: 18391726
[TBL] [Abstract][Full Text] [Related]
2. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.
Minn H; Lapela M; Klemi PJ; Grénman R; Leskinen S; Lindholm P; Bergman J; Eronen E; Haaparanta M; Joensuu H
J Nucl Med; 1997 Dec; 38(12):1907-11. PubMed ID: 9430467
[TBL] [Abstract][Full Text] [Related]
3. FDG uptake in primary squamous cell carcinoma of the head and neck. The relationship between overexpression of glucose transporters and hexokinases, tumour proliferation and apoptosis.
Deron P; Vangestel C; Goethals I; De Potter A; Peeters M; Vermeersch H; Van de Wiele C
Nuklearmedizin; 2011; 50(1):15-21. PubMed ID: 21052609
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi.
Castellani M; Carletto M; Baldini L; Calori R; Longari V; Soligo D; Dellavedova L; Gerundini P
Clin Nucl Med; 2010 Jan; 35(1):1-5. PubMed ID: 20026963
[TBL] [Abstract][Full Text] [Related]
6. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.
Yen TC; See LC; Lai CH; Yah-Huei CW; Ng KK; Ma SY; Lin WJ; Chen JT; Chen WJ; Lai CR; Hsueh S
J Nucl Med; 2004 Jan; 45(1):22-9. PubMed ID: 14734665
[TBL] [Abstract][Full Text] [Related]
8. Primary tumor standardized uptake value predicts survival in head and neck squamous cell carcinoma.
Zhang B; Geng J; Nie F; Li X
Oncol Res Treat; 2015; 38(1-2):45-8. PubMed ID: 25633888
[TBL] [Abstract][Full Text] [Related]
9. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
Kitagawa Y; Sadato N; Azuma H; Ogasawara T; Yoshida M; Ishii Y; Yonekura Y
J Nucl Med; 1999 Jul; 40(7):1132-7. PubMed ID: 10405132
[TBL] [Abstract][Full Text] [Related]
10. Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
Rose BS; Liang Y; Lau SK; Jensen LG; Yashar CM; Hoh CK; Mell LK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1185-91. PubMed ID: 22270171
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma.
Rasmussen JH; Vogelius IR; Fischer BM; Friborg J; Aznar MC; Persson GF; Håkansson K; Kristensen CA; Bentzen SM; Specht L
Head Neck; 2015 Sep; 37(9):1274-81. PubMed ID: 24801812
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer.
Machtay M; Natwa M; Andrel J; Hyslop T; Anne PR; Lavarino J; Intenzo CM; Keane W
Head Neck; 2009 Feb; 31(2):195-201. PubMed ID: 19107945
[TBL] [Abstract][Full Text] [Related]
14. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.
Kostakoglu L; Goldsmith SJ
J Nucl Med; 2004 Jan; 45(1):56-68. PubMed ID: 14734674
[TBL] [Abstract][Full Text] [Related]
15. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
16. The Feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck.
Kim SY; Lee SW; Nam SY; Im KC; Kim JS; Oh SJ; Ahn SD; Shin SS; Choi EK; Kim JH
J Nucl Med; 2007 Mar; 48(3):373-8. PubMed ID: 17332614
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.
Schwartz DL; Ford E; Rajendran J; Yueh B; Coltrera MD; Virgin J; Anzai Y; Haynor D; Lewellyn B; Mattes D; Meyer J; Phillips M; Leblanc M; Kinahan P; Krohn K; Eary J; Laramore GE
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):129-36. PubMed ID: 15629603
[TBL] [Abstract][Full Text] [Related]
18. Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging.
Simons AL; Fath MA; Mattson DM; Smith BJ; Walsh SA; Graham MM; Hichwa RD; Buatti JM; Dornfeld K; Spitz DR
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1222-30. PubMed ID: 17967311
[TBL] [Abstract][Full Text] [Related]
19. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
[TBL] [Abstract][Full Text] [Related]
20. Metabolic tumour volume. Prognostic value in locally advanced squamous cell carcinoma of the head and neck.
Deron P; Mertens K; Goethals I; Rottey S; Duprez F; De Neve W; Vermeersch H; Van de Wiele C
Nuklearmedizin; 2011; 50(4):141-6. PubMed ID: 21594304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
